HC Wainwright Reiterates Buy Rating for Conatus Pharmaceuticals Inc. (CNAT)
Conatus Pharmaceuticals Inc. (NASDAQ:CNAT)‘s stock had its “buy” rating restated by investment analysts at HC Wainwright in a note issued to investors on Thursday, MarketBeat Ratings reports. They presently have a $17.00 price target on the biotechnology company’s stock, down from their previous price target of $18.00.
CNAT has been the topic of several other reports. Stifel Nicolaus reiterated a “buy” rating and set a $10.00 target price on shares of Conatus Pharmaceuticals in a report on Thursday, August 3rd. Seaport Global Securities reiterated a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a report on Friday, October 6th. Finally, Zacks Investment Research upgraded Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 3rd. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Conatus Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $16.00.
Conatus Pharmaceuticals (NASDAQ:CNAT) last announced its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.08). The company had revenue of $9.57 million for the quarter, compared to analysts’ expectations of $16.06 million. Conatus Pharmaceuticals had a negative net margin of 80.98% and a negative return on equity of 88.06%. During the same quarter in the previous year, the business posted ($0.31) earnings per share.
WARNING: This piece of content was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece of content on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.watchlistnews.com/conatus-pharmaceuticals-inc-cnat-price-target-lowered-to-17-00-at-hc-wainwright/1672642.html.
Hedge funds and other institutional investors have recently modified their holdings of the business. Voya Investment Management LLC acquired a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $101,000. Bank of Montreal Can acquired a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $109,000. FNY Partners Fund LP grew its stake in Conatus Pharmaceuticals by 98.0% during the 2nd quarter. FNY Partners Fund LP now owns 19,800 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 9,800 shares in the last quarter. State of Wisconsin Investment Board acquired a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $115,000. Finally, Strs Ohio acquired a new stake in Conatus Pharmaceuticals during the 2nd quarter valued at approximately $153,000. Hedge funds and other institutional investors own 33.06% of the company’s stock.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
Receive News & Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.